Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.

作者信息

Montes José Manuel, Ciudad Antonio, Gascón Josep, Gómez Juan Carlos

机构信息

Centro de Salud Mental "La Plata" ("La Plata" Mental Health Center), University of Alcalá de Henares, Travesi;a de la Cañada s/n Torrejón de Ardoz, 28850, Madrid, Spain.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):667-74. doi: 10.1016/S0278-5846(03)00077-0.

DOI:10.1016/S0278-5846(03)00077-0

PMID:12787855

Abstract

OBJECTIVE

This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia.

METHOD

One hundred and eighty-two patients with first-episode schizophrenia (ICD-10) drawn from a larger, naturalistic, study were evaluated after 6 months of treatment with olanzapine, risperidone, or conventional antipsychotics (CA). Clinical status was assessed using the Clinical Global Impression-Severity (CGI-S) and Global Assessment of Function (GAF). AWAD and EuroQol scales were used to evaluate patients' attitude towards medication and Qol, respectively.

RESULTS

Subjects treated with olanzapine, risperidone, and CA showed similar improvements on CGI-S and GAF. Treatment-emergent, extrapyramidal symptoms were significantly lower in olanzapine-treated patients (17.8%) than in the risperidone (46.4%) and CA (62.2%) groups. Compared to CA, olanzapine and risperidone showed significantly greater improvement on the visual analog scale of EuroQol. Olanzapine-treated patients also showed significantly improved AWAD scores.

CONCLUSIONS

In first-episode schizophrenia, atypical antipsychotics were effective, and improved Qol. Olanzapine had a lower incidence of extrapyramidal symptoms and better subjective acceptance of medication.

摘要